Biomax Informatics AG Acquires LabVantage Solutions
Biomax Informatics AG, a management services organization, acquired LabVantage Solutions, Inc. The terms of the deal were not disclosed. Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. It is based in Germany. LabVantage Solutions, Inc. is a provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower cost. According to the LevinPro HC database, this was the 102nd Labs deal of the year. This compares with 90 Labs deals reported between Jan. 1, 2021, and Oct. 13, 2021. Read More »
BioIVT Acquires Fidelis Research in Fourth Acquisition of 2022
BioIVT, a portfolio company of private equity firm Linden Capital Partners and formerly known as BioreclamationIVT, announced on September 26 its acquisition of Fidelis Research, a Sofia, Bulgaria-headquartered provider of biospecimen collection, laboratory processing and analysis, clinical research and patient support programs. Terms of the deal were not disclosed. With this acquisition, Westbury, New York-based BioIVT will be able to expand its support of precision medicine research in multiple therapeutic areas, most notably in oncology. Fidelis Research is an 85-site clinical biospecimen collection network in southeastern Europe. The company also has cell isolation capabilities and... Read More »
Pharos Capital Group Invests in Renal Care 360°
Pharos Capital Group, LLC, a middle-market private equity firm based in Dallas and Nashville, announced on September 12 a significant investment in Renal Care 360°, a nephrology practice and chronic care management company founded by renal care entrepreneur Joe Cashia. The size and terms of the transaction were not disclosed. This marks the fourth investment from Pharos’ latest flagship fund, Pharos Capital Partners IV, L.P. Pharos’ investment, along with additional equity investment from Renal Care 360°’s founding shareholders, will be used to support continued growth of the company’s RC360° Connected Care Program, geographic expansion through acquisitions and the... Read More »
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
On December 23, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies. The transaction, which is subject to approval by both companies’ shareholders as well as customary closing conditions and regulatory approvals, is expected to close in the first half of 2022. Quidel will acquire Ortho for $24.68 per share of common stock, for a total consideration of approximately $6.0 billion, including $1.75 billion of cash, funded through cash on the balance sheet and incremental borrowings. The combined company will also acquire Ortho’s... Read More »
